This is because 13 patients (72.2%) had WHO grade 2 glioma, and 3 patients (16.7%) had WHO grade 3 glioma with isocitrate dehydrogenase 1 (IDH1) mutation, which progress slowly. The gene discussed is IDH1; the disease is central nervous system cancer.